Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: individual-patient-data meta-analysis of randomized trials [PDF]
, 2017 Background: The recommended maximum age and time window for intravenous alteplase treatment of acute ischemic stroke differs between the Europe Union and United States.
Colin Baigent +28 more
core +5 more sources
Effect of alteplase on platelet function and receptor expression
Journal of International Medical Research, 2019 Objective To investigate the role of alteplase, a widely-used thrombolytic drug, in platelet function. Methods Human platelets were incubated with different concentrations of alteplase followed by analysis of platelet aggregation in response to adenosine
Jun Lu +5 more
doaj +1 more source
JAMA Internal Medicine, 2023 Importance Current guidelines advise against intravenous alteplase therapy for treatment of acute ischemic stroke in patients previously treated with non-vitamin K antagonist oral anticoagulants (NOACs).
Tou-Yuan Tsai +9 more
semanticscholar +1 more source
Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) [PDF]
, 2008 <p><b>Background and Purpose:</b> The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with ...
Ahmed, Niaz +19 more
core +2 more sources
Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke
European Stroke Journal, 2023 Introduction: Alteplase is widely used as an intravenous thrombolytic drug in acute ischemic stroke (AIS). Recently however, tenecteplase, a modified form of tissue plasminogen activator, has been shown to increase early recanalization rate and has ...
C. Nguyen +6 more
semanticscholar +1 more source
Thrombolysis in very elderly people: controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive [PDF]
, 2010 <p>Objective To assess effect of age on response to alteplase in acute ischaemic stroke.</p> <p>Design Adjusted controlled comparison of outcomes between non-randomised patients who did or did not undergo thrombolysis.
Ahmed, N. +7 more
core +1 more source
Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase
Stroke, 2023 BACKGROUND: Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke.
T. Checkouri +12 more
semanticscholar +2 more sources
Stroke, 2023 Background: Prior systematic reviews have compared the efficacy of intravenous tenecteplase and alteplase in acute ischemic stroke, assigning their relative complications as a secondary objective.
Deborah Rose +18 more
semanticscholar +1 more source
Professional guideline versus product label selection for treatment with IV thrombolysis: an analysis from SITS registry [PDF]
, 2017 Introduction: Thrombolysis usage in ischaemic stroke varies across sites. Divergent advice from professional guidelines and product labels may contribute. Patients and methods: We analysed SITS-International registry patients enrolled January 2010
Alan C Cameron +8 more
core +1 more source
medRxiv, 2023 BACKGROUND: The AcT (Alteplase Compared to Tenecteplase) randomized controlled trial showed that tenecteplase is noninferior to alteplase in treating patients with acute ischemic stroke within 4.5 hours of symptom onset.
N. Singh +33 more
semanticscholar +1 more source